| Name | Title | Contact Details |
|---|
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side by side with our clients, we strive to move drug discovery forward, helping develop life-saving and life-improving drugs. PRA has more than 10,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, we have worked on 100 plus marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50 plus such drugs.
Guadalupe Regional Medical Center is committed to providing sophisticated facilities and services with an emphasis on personalized care.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Standard Homeopathic Co (Hylands) is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Carson, CA. To find more information about Standard Homeopathic Co (Hylands), please visit www.hylands.com
The new Actavis, Inc. (NYSE:ACT) is a combination of the previously separate Watson Pharmaceuticals, Inc. and Swiss-based Actavis Group. Actavis, Inc. is a specialty pharmaceutical company that develops, manufactures and distributes generic, brand and biosimilar products. The Company has global headquarters in Parsippany, NJ and international headquarters in Zug, Switzerland.